Targets › SLC22A16
6 programs from 4 companies in 7 trials: 5 Phase 3, 2 Phase 2; Oncology; next expected readout Feb 2027.
Facilitative organic cation transporter that mediates the transport of carnitine as well as the polyamine spermidine. Mediates the partially Na(+)-dependent bidirectional transport of carnitine. (UniProt, Q86VW1)
Open in Phaseline: the race on SLC22A16, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Centre Hospitalier Universitaire Dijon | modified FOLFOX Multi-drug chemotherapy: folate antagonist (folinic acid), thymidylate synthase inhibitor | TOPO2, TYMS, DHFR, SLC22A16 | Phase 3 | Colon Cancer; Locally Advanced or Metastatic Small Bowel Adenocarcinoma | Feb 2027 |
| Tehran University of Medical Sciences | Drug-Eluting Embolic Bead (DEBIRI) Irinotecan-loaded drug-eluting beads for transarterial chemoembolization | SLC22A16 | Phase 3 | Liver Neoplasm | Oct 2027 |
| Fudan University | XELOX adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent) and capecitabine (5-fluorouracil pr | DHFR, TYMS, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| Fudan University | mFOLFIRINOX adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent), irinotecan (topoisomerase I inhibi | DHFR, TYMS, TOPO1, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| Fudan University | mFOLFOX6 adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent), leucovorin (folinic acid), and 5-f | DHFR, TYMS, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| CRISM Therapeutics | irinotecan-ChemoSeed Irinotecan-releasing implant for local chemotherapy in glioblastoma resection cavity | SLC22A16 | Phase 2 | Glioblastoma | May 2029 |
High-risk Stage II Colorectal Cancer (3) Colon Cancer (1) Locally Advanced or Metastatic Small Bowel Adenocarcinoma (1) Glioblastoma (1) Liver Neoplasm (1)
small molecule (5)
Fudan University (3) Centre Hospitalier Universitaire Dijon (1) CRISM Therapeutics (1) Tehran University of Medical Sciences (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.